Vertex is also developing a version called VX-264 in which the cells are encapsulated in a protective device designed to protect them from rejection by the immune system. A phase 1/2 trial of VX ...

Vertex stock is significantly undervalued due to the underestimated potential of its pain treatment drug, VX-548, which could become a blockbuster. VX-548 has shown to be more effective than ...

At VXSW, we are dedicated to developing intuitive, tailored solutions for niche challenges. We strive to tackle complex problems with simplicity and efficiency ...

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $470.78, moving -0.07% from the previous trading session. The stock's change was less than the S&P 500's daily gain of 0.45%.

You can create a release to package software, along with release notes and links to binary files, for other people to use. Learn more about releases in our docs.

VX-880 (formerly known as STx-02) derives from Vertex’ near $1 billion acquisition of Semma in 2019, and has started enrolling patients in a phase 1/2 study in the US. The therapy takes the form ...

And we intend to fully develop both of these markets at Vertex. We see them both as specialty markets. And longer-term, given the mechanism of action, we know from our predecessor molecule VX-150 ...

No patients have received Casgevy, CRISPR Therapeutics and Vertex Pharmeceuticals’ recently approved sickle cell gene therapy. Experts weigh in on the path to profit for the treatment and the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Commissions do not affect our editors' opinions or evaluations. Customer relationship management (CRM) software is a tool that helps salespeople and businesses manage interactions with prospects ...